Nutriband (NASDAQ:NTRB) Shares Break Above 50-Day Moving Average – Time to Sell?

Nutriband Inc. (NASDAQ:NTRB) crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $6.25 and traded as high as $6.41. Nutriband shares last traded at $6.4750, with a volume of 71,074 shares trading hands.

Analyst Ratings Changes

Several research firms have commented on NTRB. Weiss Ratings reissued a “sell (d-)” rating on shares of Nutriband in a research note on Monday, September 28th. Wall Street Zen upgraded shares of Nutriband to a “hold” rating in a report on Saturday, October 17th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Reduce”.

Nutriband Price Performance

The company has a market capitalization of $78.71 million, a P/E ratio of -12.22 and a beta of 1.92. The company has a 50 day moving average of $6.25 and a 200-day moving average of $4.35.

Nutriband (NASDAQ:NTRB) last announced its quarterly earnings results on Friday, September 4th. The company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $0.44 million for the quarter. Nutriband had a negative net margin of 430.35% and a negative return on equity of 109.07%.

Nutriband Company Profile

Nutriband Inc is a medical technology company focused on developing and commercializing transdermal and topical products. The company’s platform is designed to deliver active pharmaceutical ingredients through the skin, with applications in prescription medicines, over-the-counter products, consumer health, and veterinary care.

Nutriband also provides contract manufacturing and product development services for transdermal patches and related products. Its offerings include adhesive patches and other topical delivery formats, as well as formulation, manufacturing, packaging, and regulatory support for customers developing transdermal therapies.

The company’s proprietary AVERSA technology is intended to incorporate abuse-deterrent and tamper-resistant features into transdermal drug-delivery systems.